“…The current EAACI/GA(2)LEN/EDF/WAO guidelines recommend using omalizumab, ciclosporin, or montelukast in patients who are unresponsive to up to fourfold dosed non-sedating antihistamines [3]. Additional therapeutics that have been tried in CSU include colchicine [37], mesalazine [38], hydroxychloroquine [39], dapsone [40,41], sulfasalazine [42], corticosteroids [43], narrowband ultraviolet B phototherapy [44], doxepin [45,46], mycophenolate mofetil [47,48], methotrexate [49][50][51], plasmapheresis [52], miltefosine [53], and intravenous immunoglobulin (IVIG) [54][55][56]. The vast majority of these have been used in small case reports and case series, but not in randomized controlled trials (RCTs) [ Table 1].…”